Literature DB >> 14723729

Progressive osseous heteroplasia resulting from a new mutation in the GNAS1 gene.

I Chan1, T Hamada, C Hardman, J A McGrath, F J Child.   

Abstract

Progressive osseous heteroplasia (OMIM 166350) is a rare autosomal dominant condition that presents in childhood as dermal ossification and may progress deeper to involve subcutaneous fat and connective tissue. Recently, paternally inherited inactivating mutations in the GNAS1 gene on chromosome 20q13 have been implicated in the pathogenesis, although sporadic cases have also been reported. We report a 9-year-old British Chinese girl with progressive osseous heteroplasia resulting from a de novo missense mutation (W281R) in the GNAS1 gene. She is of small stature (0.4th centile) and started to develop skin lesions at the age of 9 months. These have been confirmed histologically as osteoma cutis. She is of normal intelligence and development and has no dysmorphic features. The GNAS1 gene exhibits imprinting and maternally inherited mutations have previously been shown to result in Albright's hereditary osteodystrophy (OMIM 103580) with pseudohypothyroidism type 1a, whereas paternally inherited mutations result in progressive osseous heteroplasia or the Albright's hereditary osteodystrophy phenotype with pseudopseudohypothyroidism (OMIM 300800). With only nine mutations of the GNAS1 gene reported so far in progressive osseous heteroplasia, this new mutation helps to extend further the genotype-phenotype correlation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14723729     DOI: 10.1111/j.1365-2230.2004.01439.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  9 in total

Review 1.  Adipose-derived stem cells for regenerative medicine.

Authors:  Jeffrey M Gimble; Adam J Katz; Bruce A Bunnell
Journal:  Circ Res       Date:  2007-05-11       Impact factor: 17.367

2.  Chronic ulcers, calcification and calcified fibrous tumours: phenotypic manifestations of a congenital disorder of heterotopic ossification.

Authors:  Susanne Kupitz; Stuart Enoch; Keith G Harding
Journal:  Int Wound J       Date:  2007-09       Impact factor: 3.315

3.  Extralarge XL(alpha)s (XXL(alpha)s), a variant of stimulatory G protein alpha-subunit (Gs(alpha)), is a distinct, membrane-anchored GNAS product that can mimic Gs(alpha).

Authors:  Cumhur Aydin; Nurgul Aytan; Mathew J Mahon; Hesham A W Tawfeek; Neil W Kowall; Alpaslan Dedeoglu; Murat Bastepe
Journal:  Endocrinology       Date:  2009-05-07       Impact factor: 4.736

4.  A high-throughput siRNA library screen identifies osteogenic suppressors in human mesenchymal stem cells.

Authors:  Yuanxiang Zhao; Sheng Ding
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

5.  Pseudohypoparathyroidism type 1a and insulin resistance in a child.

Authors:  Benjamin U Nwosu; Mary M Lee
Journal:  Nat Rev Endocrinol       Date:  2009-06       Impact factor: 43.330

6.  Total Ankylosis of the Upper Left Limb: A Case of Progressive Osseous Heteroplasia.

Authors:  Ali Birjandinejad; Mohammad-Hossein Taraz-Jamshidi; Sayyed Hadi Sayyed Hosseinian
Journal:  Arch Bone Jt Surg       Date:  2016-06

Review 7.  GNAS mutations in Pseudohypoparathyroidism type 1a and related disorders.

Authors:  Manuel C Lemos; Rajesh V Thakker
Journal:  Hum Mutat       Date:  2014-11-28       Impact factor: 4.878

8.  The GNAS Locus: Quintessential Complex Gene Encoding Gsalpha, XLalphas, and other Imprinted Transcripts.

Authors:  Murat Bastepe
Journal:  Curr Genomics       Date:  2007-09       Impact factor: 2.236

9.  Case Report: Two Monochorionic Twins With a Critically Different Course of Progressive Osseus Heteroplasia.

Authors:  Antonio José Justicia-Grande; Jose Gómez-Ríal; Irene Rivero-Calle; Sara Pischedda; María José Curras-Tuala; Alberto Gómez-Carballa; Miriam Cebey-López; Jacobo Pardo-Seco; Roberto Méndez-Gallart; María José Fernández-Seara; Antonio Salas; Federico Martinón-Torres
Journal:  Front Pediatr       Date:  2021-06-23       Impact factor: 3.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.